Jesús Zurdo, Rebecca Michael and Yvette Stallwood at Lonza Biologics, and Karin Hedman and Teodor Aastrup at Attana AB of Biopharmaceuticals

The combination of computational and protein engineering tools with novel orthogonal methods of measuring aggregation can be used to assess the developability of biopharm products in the early stages of development, thereby reducing the level of risk in later stages.

Jesús Zurdo, Rebecca Michael and Yvette Stallwood at Lonza Biologics, and Karin Hedman and Teodor Aastrup at Attana AB (June 2011)

View full article    |    Back to Manufacturing section